您当前的位置：

Sotorasib

(Synonyms: 索托拉西布; AMG-510)

目录号: PL10880 纯度: ≥99%

Sotorasib (AMG-510) 是一种有效的，口服生物可利用的，选择性的 KRAS G12C 共价抑制剂。Sotorasib 将 KRAS G12C 锁定在非活跃的 GDP 约束状态。Sotorasib 是临床开发的第一个 KRAS G12C 抑制剂，能使 KRAS G12C 肿瘤消退。

CAS No. :2296729-00-3

商品编号	规格	价格	会员价
PL10880-5mg	5mg	¥1055.00	请登录
PL10880-10mg	10mg	¥1655.00	请登录
PL10880-50mg	50mg	¥4605.00	请登录
PL10880-100mg	100mg	¥6565.00	请登录
PL10880-200mg	200mg	询价	询价
PL10880-500mg	500mg	询价	询价
PL10880-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2775.00	请登录
PL10880-1 mL x 10 mM (in DMSO)		¥1285.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Sotorasib
中文别名	6-氟-7-（2-氟-6-羟基苯基）-1-（4-甲基-2-丙基-2-基吡啶-3-基）-4-[（2S）-2-甲基-4-丙-2-烯酰基哌嗪-1-基]吡啶并[2，3-d]嘧啶-2-酮;索托拉西布;AMG510单一构型;(1R)-6-氟-7-(2-氟-6-羟基苯基)-1-[4-甲基-2-(1-甲基乙基)-3-吡啶基]-4-[(2S)-2-甲基-4-(1-氧代-2-丙烯-1-基)-1-哌嗪基]-吡啶并[2,3-D]嘧啶-2(1H)-酮;索托拉西;索托拉司;SOTORASIB单一构型;AMG 510游离态;AMG510(索托拉西布)
英文名称	Sotorasib
英文别名	AMG510;Kras G12C inhibitor 9;2B2VM6UC8G;AMG 510;6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one;GTPL10678;BCP30452;s8830;DB15569;Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl;CID 137278711;Sotorasib;PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE, 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-[4-METHYL-2-(1-METHYLETHYL;Pyrido[2,3-d]pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-, (1R)-;AMG-510(Sotorasib);Storasib;Pyrido[2,3-d]pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-, (1R)- 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
Cas No.	2296729-00-3
分子式	C₃₀H₃₀F₂N₆O₃
分子量	560.59
包装储存	-20°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
详情描述	Sotorasib (AMG-510) 是一种有效的，口服生物可利用的，选择性的 KRAS G12C 共价抑制剂。Sotorasib 将 KRAS G12C 锁定在非活跃的 GDP 约束状态。Sotorasib 是临床开发的第一个 KRAS G12C 抑制剂，能使 KRAS G12C 肿瘤消退。

产品详情

生物活性

Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors.

性状

Solid

IC50 & Target[1][2]

KRAS(G12C)

体外研究(In Vitro)

In cellular assays, Sotorasib (AMG-510) covalently modifies KRAS G12C and inhibits KRAS G12C signaling as measured by phosphorylation of ERK1/2 (p-ERK) in all KRAS p.G12C -mutant cell lines.
Sotorasib (AMG-510; 1-10 μM; 72 hours) also potently impairs cellular viability in both NCI-H358 and MIA PaCa-2 with IC50≈0.006 μM and 0.009 μM, respectively. Non-KRASG12C lines are insensitive to Sotorasib (IC50>7.5 μM). has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

In preclinical tumor models, Sotorasib (AMG-510) rapidly and irreversibly binds to KRAS G12C, providing durable suppression of the mitogen-activated protein kinase (MAPK) signaling pathway. Sotorasib (orally; once daily) is capable of inducing tumor regression in mouse models of KRAS G12C cancer. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

ClinicalTrial

参考文献

[1]. Marwan Fakih, et al, Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12Cinhibitor, in advanced solid tumors. Journal of Clinical Oncology.
[2]. Karen Rex, et al. Abstract 3090: In vivo characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models. Experimental and Molecular Therapeutics.

溶解度数据	In Vitro: DMSO : 50 mg/mL (89.19 mM; Need ultrasonic)H₂O : 33.33 mg/mL (59.46 mM; ultrasonic and adjust pH to 11 with NaOH)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Sotorasib

相关产品

The molarity calculator equation

The dilution calculator equation